ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 27TH ANNUAL J.P.
MORGAN HEALTHCARE CONFERENCE
GHENT, Belgium, 12 January 2009 - Ablynx [Euronext Brussels: ABLX], a
pioneer in the discovery and development of Nanobodies®, a novel
class of antibody-derived therapeutic proteins, today announced that
it will webcast its corporate presentation at the 27th Annual J.P.
Morgan Healthcare Conference on Wednesday, 14 January 2009 at 11.00
a.m. PST / 08.00 p.m. CET.
The presentation, followed by a Q&A, will be hosted by Dr Edwin
Moses, CEO and Chairman at Ablynx. This will be webcast live and may
be accessed on the home page of Ablynx's website at www.ablynx.com. A
replay of the webcast will also be available on the Company's website
for 90 days, by default (until 15 April 2009).
To ensure a timely connection, it is recommended that users register
at least 10 minutes prior to the scheduled webcast.
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical
company focused on the discovery and development of Nanobodies®, a
novel class of therapeutic proteins based on single-domain antibody
fragments, for a range of serious and life-threatening human
diseases. The Company currently has over 200 employees. Ablynx
completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007.
Ablynx is developing a portfolio of Nanobody®-based therapeutic
programmes in a number of major disease areas, including
inflammation, thrombosis, oncology and Alzheimer's disease.
Nanobodies® have been generated against more than 100 different
disease targets. Efficacy data has been obtained in over 25 in vivo
models for Nanobodies® against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies®
for healthcare applications. It has exclusive and worldwide rights to
more than 50 families of granted patents and pending patent
applications, including the Hamers patents covering the basic
structure, composition, preparation and uses of Nanobodies®.
For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John McIntyre
t: +44 (0)20 7866 7857
f: +44 (0)20 7866 7900
e: ablynx@collegehill.com
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
http://hugin.info/137912/R/1281672/286660.pdf
Copyright © Hugin AS 2009. All rights reserved.